Aizen Enters into Collaboration with San Diego Biopharma to Advance Oral Biologics
Multi-program deal with revenue potential of $100 million per target SAN DIEGO, Aug. 15, 2026 /PRNewswire/ -- Aizen Therapeutics, an AI-native biotechnology company focused on building oral biologics, today announced a multi-program collaboration with a San D…


